8-K
Current Report
Fulcrum Therapeutics, Inc. Filed Acc 0000950170-24-109069
Exit or restructuring costs
- Item 2.05 Costs associated with exit or disposal activities
From the SEC's structured data for this filing
Loading fulc-20240924.htm…